Leren P, Foss P O, Nordvik B, Fossbakk B
Oslo University Medical School, Norway.
Acta Med Scand. 1988;223(4):321-6. doi: 10.1111/j.0954-6820.1988.tb15880.x.
In a 24-week randomized, single-blind study Timolol (n = 63) and Enalapril (n = 57) proved to be potent and safe antihypertensive drugs. However, the effect on lipid metabolism was fundamentally different, despite the fact that the effect on total serum cholesterol did not significantly differ between the two groups. Enalapril had no adverse effect on any lipid fractions, while Timolol increased very low (VLDL) + low (LDL) density lipoprotein cholesterol by 7.6% (p less than 0.001) and total triglycerides by 34.5% (p less than 0.001), and decreased the favorable high density lipoprotein (HDL) cholesterol by 11.3% (p less than 0.001). Thus, the ratio HDL/VLDL + LDL cholesterol was reduced by 17.1% (p less than 0.001). Enalapril reduced uric acid by 3.4% (NS), while Timolol increased uric acid by 4.0% (p less than 0.05). The difference between the groups was statistically significant (p less than 0.01). The first steps in any attempt to solve the hypertension-coronary dilemma should be to take into consideration all pharmacologic effects of antihypertensive drugs.
在一项为期24周的随机、单盲研究中,噻吗洛尔(n = 63)和依那普利(n = 57)被证明是强效且安全的抗高血压药物。然而,尽管两组对总血清胆固醇的影响无显著差异,但它们对脂质代谢的影响却截然不同。依那普利对任何脂质成分均无不良影响,而噻吗洛尔使极低密度脂蛋白(VLDL)+低密度脂蛋白(LDL)胆固醇升高了7.6%(p < 0.001),总甘油三酯升高了34.5%(p < 0.001),并使有益的高密度脂蛋白(HDL)胆固醇降低了11.3%(p < 0.001)。因此,HDL/VLDL + LDL胆固醇的比值降低了17.1%(p < 0.001)。依那普利使尿酸降低了3.4%(无统计学意义),而噻吗洛尔使尿酸升高了4.0%(p < 0.05)。两组之间的差异具有统计学意义(p < 0.01)。在任何试图解决高血压 - 冠心病困境的尝试中,首要步骤都应是考虑抗高血压药物的所有药理作用。